This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: Suspensions delivered via a pressurized metered-dose inhaler (pMDI) require shaking the canister before actuation to prevent drug sedimentation. We hypothesized that a shake-actuation delay of an albuterol hydrofluoroalkane (HFA) pMDI will increase and decrease delivered dose (DOSE) at the beginning and end of the canister’s life, respectively, and that aerosol characteristics will remain unchanged with the delay.
METHODS: Albuterol HFA pMDIs (90 µg/actuation, 200 doses) operated with and without a 30-s shake-actuation delay, and with and without a valved holding chamber (VHC), were studied. Ten puffs, with a 30-s interval between puffs and 5s of shaking, were actuated into a drug-recovery apparatus. Inhalers were studied throughout their entire life (from 200 doses to 0 remaining doses). Particle size analysis was performed with cascade impaction at the beginning, middle, and end of the canister’s life. Albuterol mass was determined via spectrophotometry (276 nm).
RESULTS: Mean (99% CI) delivered dose without shake-actuation delay was 100.4% (98.1–102.9%) of the nominal dose. Mean (99% CI) delivered dose with a VHC without a shake-actuation delay was 48.6% (46.2–50.9%) of the nominal dose. The shake-actuation delay increased and decreased delivered dose at the beginning and end of the canister’s life, respectively, irrespective of VHC use. Decline in delivered dose began when 110–120 doses remained in the canister. Aerosol characteristics remained constant throughout the canister’s life except for the amount of drug captured by the impactor for the pMDI with delay and the pMDI/VHC with delay. Adding a VHC to a pMDI operated with a delay increased fine-particle fraction and decreased the amount of drug captured by the impactor at the middle and at the end of the canister’s life.
CONCLUSIONS: A 30-s shake-actuation delay of an albuterol HFA pMDI increased and decreased delivered dose at the beginning and end of canister’s life, respectively. Particle size characteristics at the end of the canister’s life changed when the pMDI and pMDI/VHC were operated with a shake-actuation delay. Patients should re-shake the pMDI if it is not actuated immediately after shaking the canister.
Footnotes
- Correspondence: Ariel Berlinski MD FAARC, 1 Children’s Way, Slot 512–17, Little Rock, AR 72212. E-mail: berlinskiariel{at}uams.edu
Dr Qaqish presented a version of this paper at the 2020 American Thoracic Society Virtual Conference, held August 5 through November 10, 2020.
This work was partially supported by the James H. Hamlen II Endowed Chair in Pediatric Pulmonology funds (Arkansas Children’s Hospital). Dr Berlinski has disclosed relationships with AbbVie, Allergan, Anthera, DCI, Cempra, Cystic Fibrosis Foundation, National Institute of Health, Novartis, Therapeutic Development Network, Trudell Medical International, Vertex, Vivus, and the International Pharmaceutical Aerosol Consortium on Regulation and Science. Dr Qaqish has disclosed no conflicts of interest.
- Copyright © 2021 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.